Drug having no analogues in Russia is developed in Ufa

Arina Rakhimkulova

UFA, 20 August 2015. /Bashinform News Agency, Arina Rakhimkulova/. A new drug for treatment of musculoskeletal system, which has no analogues in the Russian pharmaceutical market, is developed in Ufa. A patent was granted to R&D Company "Microgen", in Ufa branch of which a unique technology of effective post-treatment of an aqueous solution of active drug substance "Hondrolon-Pro" was created. The drug is intended for treatment of degenerative diseases of the peripheral synovial joints and spine.

As told by the company's specialists, in contrast to other injectable chondroprotective medicines, the Ufa innovation has stable physical and chemical properties, without addition of an antimicrobial preservative, which may be toxic.

In a series of successive biotech operations samples an improved quality, stable therapeutic effect and a high level of safety were obtained.

In 2014, the volume of sales of injective disease-modifying drugs in Russia amounted to about 4.5 billion rubles. Such drugs were mainly represented by manufacturers of Romania and Germany. The industrial output of the drug will begin after the end of clinical trials, the press service of the R&D Company "Microgen" informs.

#drug #disease-modifying #chondroprotective

Join us for more and faster updates on our social media.:

Rubrics

Phone

Office: +7(347) 250-05-07 Advertising office: +7(347) 250-11-11 Editors office: +7(347) 250-07-28 Cooperation: +7(347) 250-06-14

inf@bashinform.ru

Address

450077, Ufa, Kirov street, 45

© 1992-2026 Bashinform News Agency JSC. Mass Media Registration Certificate No. TU 02-01609 dated September 25, 2017, issued by the Office of the Federal Service for Supervision of Communications, Information Technology and Mass Media for the Republic of Bashkortostan.

All information and content posted on the website www.bashinform.ru are protected by international and Russian copyright and related rights legislation. All reports by the Bashinform News Agency are intended for users over 18 years of age.

When reprinting or quoting, a reference to Bashinform News Agency is mandatory. For online publications and social media, a direct active hyperlink is required. Using the Bashinform News Agency logo for purposes not related to the agency when reprinting or quoting is permitted only with the written permission of JSC Bashinform News Agency.